138 related articles for article (PubMed ID: 37439295)
1. PubPredict: Prediction of progression and survival in oncology leveraging publications and early efficacy data.
Zhang J; Guo Y; Zhou J; Rasmussen HE
Pharm Stat; 2023; 22(5):963-973. PubMed ID: 37439295
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
Hu C; Wang M; Wu C; Zhou H; Chen C; Diede S
JAMA Netw Open; 2021 May; 4(5):e218175. PubMed ID: 34047794
[TBL] [Abstract][Full Text] [Related]
4. A multistate model for early decision-making in oncology.
Beyer U; Dejardin D; Meller M; Rufibach K; Burger HU
Biom J; 2020 May; 62(3):550-567. PubMed ID: 31310368
[TBL] [Abstract][Full Text] [Related]
5. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
[TBL] [Abstract][Full Text] [Related]
7. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
8. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.
Zhu R; Lu D; Chu YW; Chai A; Green M; Zhang N; Jin JY
AAPS J; 2017 May; 19(3):669-681. PubMed ID: 28224402
[TBL] [Abstract][Full Text] [Related]
11. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
13. The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
Woodford RG; Zhou DD; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK
Cancer; 2022 Apr; 128(7):1449-1457. PubMed ID: 34985773
[TBL] [Abstract][Full Text] [Related]
14. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
15. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
[TBL] [Abstract][Full Text] [Related]
16. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
17. OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials.
Shameer K; Zhang Y; Prokop A; Nampally S; N IKA; Weatherall J; Iacona RB; Khan FM
JCO Clin Cancer Inform; 2022 Mar; 6():e2100173. PubMed ID: 35467964
[TBL] [Abstract][Full Text] [Related]
18. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
19. Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.
Tang Y; Bycott P; Akerborg O; Jönsson L; Negrier S; Chen C
Cancer Manag Res; 2014; 6():365-71. PubMed ID: 25278784
[TBL] [Abstract][Full Text] [Related]
20. A multistate platform model for time-to-event endpoints in oncology clinical trials.
Lin CW; Nagase M; Doshi S; Dutta S
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):154-167. PubMed ID: 37860956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
